Summit Therapeutics (SMMT) EBT (2019 - 2024)
Summit Therapeutics (SMMT) reported EBT of -$65.6 million for Q4 2024, down 81.23% on a YoY basis from -$349.6 million in Q1 2024, and down 7.88% quarter-over-quarter from -$60.8 million in Q3 2024.
Summit Therapeutics (SMMT) EBT (2019 - 2024) Analysis & Trends
Summit Therapeutics has reported EBT for 6 years, with the latest figure at -$65.6 million in Q4 2024.
- For the quarter ending Q4 2024, EBT fell 81.23% year-over-year to -$65.6 million; the trailing twelve-month figure through Dec 2024 stood at -$234.7 million (up 61.51% YoY), and the FY2024 full-year result was -$234.7 million, up 61.84% from the prior year.
- EBT for Q4 2024 stood at -$65.6 million, down from -$60.8 million in the prior quarter.
- The five-year high for EBT was -$6.1 million in Q1 2020, with the low at -$537.2 million in Q1 2023.
- Historically, EBT has averaged -$52.9 million across 5 years, with a median of -$20.4 million in 2022.
- Annual changes were most pronounced in 2023 — EBT slumped 2324.2% — and 2024, when it surged 91.53%.
- Summit Therapeutics' EBT stood at -$13.6 million in 2020, then tumbled by 99.82% to -$27.1 million in 2021, then climbed by 25.09% to -$20.3 million in 2022, then plunged by 78.38% to -$36.2 million in 2023, then tumbled by 81.23% to -$65.6 million in 2024.
- The last three EBT figures came in at -$65.6 million (Q4 2024), -$60.8 million (Q3 2024), and -$62.7 million (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 19.60 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -15.31 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | -3.18 Mn |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.25 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -56.48 Mn |
| 10 | Summit Therapeutics | 11.10 Bn | 10.99 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -65.62 Mn |
| Sep 30, 2024 | -60.83 Mn |
| Jun 30, 2024 | -62.72 Mn |
| Mar 31, 2024 | -45.51 Mn |
| Dec 31, 2023 | -36.21 Mn |
| Sep 30, 2023 | -20.49 Mn |
| Jun 30, 2023 | -15.79 Mn |
| Mar 31, 2023 | -537.15 Mn |
| Dec 31, 2022 | -20.30 Mn |
| Sep 30, 2022 | -16.94 Mn |
| Jun 30, 2022 | -12.69 Mn |
| Mar 31, 2022 | -22.16 Mn |
| Dec 31, 2021 | -27.10 Mn |
| Sep 30, 2021 | -19.60 Mn |
| Jun 30, 2021 | -24.42 Mn |
| Mar 31, 2021 | -17.49 Mn |
| Dec 31, 2020 | -13.56 Mn |
| Sep 30, 2020 | -17.80 Mn |
| Jun 30, 2020 | -15.47 Mn |
| Mar 31, 2020 | -6.08 Mn |